CardioVascular BioTherapeutics Announces Diabetic Wounds Drug Phase II Clinical Trial Data

LAS VEGAS, Jan. 4, 2011 /PRNewswire/ -- CardioVascular BioTherapeutics, Inc. (Pink Sheets: CVBT) today released summary Phase IIa and Phase IIb clinical trial data for CVBT's biological therapy to treat diabetic wounds, CVBT-141B. CVBT's Phase II data indicates that CVBT's FGF-1 biological drug appears to be delivering efficacy at a level significantly greater than has been seen in any other treatments, for patients suffering from chronic ischemic diabetic wounds.

The results of the two randomized, double-blind, placebo-controlled Phase II trials are summarized as follows: In the Phase IIa trial, diabetic wounds treated with FGF-1 healed approximately 4.5 times faster than wounds treated with placebo/standard of care (which included debridement). In the Phase IIb trial, all of the diabetic wounds treated with FGF-1 achieved 100% closure within five months or less, whereas a full one-third of the placebo-treated wounds remained open at the end of the same treatment period. Additionally, 57% of patients treated with FGF-1 had complete closure of their diabetic wounds at eight weeks, versus 0% for the placebo group. Both Phase II trials demonstrated statistical significance to placebo (p<0.05). In all trials (Phase I and Phase II), there have been no significant safety or adverse events attributable to the drug.

CVBT's CEO, Daniel C. Montano, stated: "This is extremely significant medical treatment news for diabetes patients, because CVBT-141B appears to be delivering a major treatment breakthrough for the treatment of chronic ischemic diabetic wounds. There is currently great medical need to more effectively treat diabetic wounds, to more rapidly close the wounds and avoid infections that all too often lead to amputations and worse. Current treatment options do not work for a large percentage of diabetes patients. With this Phase I and Phase II clinical trial data, CVBT plans to request FDA approval to commence a pivotal Phase III trial for CVBT-141B. Additionally, CVBT plans to apply for 'Fast Track Development Program' status for CVBT-141B."

There are 13.5 million diabetic ulcers globally, and the incidence is growing at nearly 10% annually, according to MedMarket Diligence, LLC; report #S247. The annual management cost of skin ulcers is greater than $20 billion in the U.S. alone according to Drexel University's NIR Device for Predicting Diabetic Wound Healing, 2009.

About CardioVascular BioTherapeutics

CVBT is a biopharmaceutical company developing drug candidates with FGF-1 as its active pharmaceutical ingredient (API) for diseases characterized by inadequate blood flow to tissue or organs. The company has a Phase II trial to treat severe coronary heart disease (CVBT-141H) underway, and has received FDA authorization for a Phase I trial to treat peripheral arterial disease (CVBT-141C). CVBT initiated its diabetic wound healing program in 2004, and completed an FDA-authorized Phase I study in diabetic patients in 2008. In the Phase I study, CVBT demonstrated that FGF-1 was well tolerated and showed no adverse effects when applied topically to diabetic wounds. To accelerate CVBT's wound healing program, the company recently completed a licensing agreement to obtain pre-clinical and clinical trial data for FGF-1 in dermal wound healing indications, including human data from Phase IIa and Phase IIb FDA clinical trials. A Phase III trial to treat diabetic wounds (CVBT-141B) is planned, pending FDA approval.

This news release contains forward-looking statements that involve risks and uncertainties. Actual results and outcomes may differ materially from those discussed or anticipated. For example, statements regarding expectations for new research, progress with clinical trials or future business initiatives are forward-looking statements. Factors that might affect actual outcomes include, but are not limited to, FDA approval of CVBT drug candidates, market acceptance of CVBT products by customers, new developments in the industry, future revenues, future expenses, future margins, cash usage and financial performance. For a more detailed discussion of these and associated risks, see the company's most recent documents filed with the Securities and Exchange Commission.

Media Contact:

Allison Caplan

CardioVascular BioTherapeutics, Inc.

(702) 839-7200

[email protected]

SOURCE CardioVascular BioTherapeutics, Inc.

Suggested Articles

Denali is partnering with Biogen on its Parkinson's disease program, netting a $560 million upfront fee and a $465 million investment.

In the first half of 2020, the regenerative medicine sector raised $10.7 billion, more than the total it raised in 2019.

The trial linked RG6346 to reductions in hepatitis B surface antigen that suggest the RNAi therapy can hold its own against drugs from J&J and Vir.